Safety and Efficacy of CKDB-501A in Subjects With Moderate-to-severe Glabellar Lines
NCT05292638
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
30
Enrollment
INDUSTRY
Sponsor class
Conditions
Glabellar Lines
Interventions
DRUG:
CKDB-501A
DRUG:
Botox®
Sponsor
CKD Bio Corporation